BC-1175
BC-1175 (CB-181963) is a novel cephalosporin and antibacterial agent. CB-181963 displays strong binding to altered PBP 2a. CB-181963 demonstrates marked efficacy against MRSA, Klebsiella pneumoniae, Streptococcus pneumoniae, and Escherichia coli.
For research use only. We do not sell to patients.
- CAS No.: 635292-67-0
- Formula: C19H24FN11O5S2
- Molecular Weight:569.59
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Chemical Information
-
CAS No. 635292-67-0
-
Molecular Weight 569.59
-
Formula C19H24FN11O5S2
-
SMILES
OC(C1=C(/C=N/N(C)C(N2CCNCC2)=N)CS[C@@]([C@@H]3NC(/C(C4=NSC(N)=N4)=N\OCF)=O)([H])N1C3=O)=O
-
Synonyms
CB-181963
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
[1]. Miller K, et al. Antistaphylococcal activity of the novel cephalosporin CB-181963 (CAB-175). J Antimicrob Chemother. 2005 Apr;55(4):579-82. [Content Brief]
[2]. Huang V, et al. In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci. Antimicrob Agents Chemother. 2004 Jul;48(7):2719-23. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BC-1175 Related Classifications
HY-107053 Related Classifications
Powered by Bioz